IQVIA SOLUTIONS ASIA PTE. LTD.
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Computer Processing and Data Preparation and Processing Services, Information Retrieval Services), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about IQVIA SOLUTIONS ASIA PTE. LTD.
Live alerts from global media, monitored by Business Radar
2025-04-01 (shinailbo.co.kr)
Yuhan Corporation 'La La Ola', Arginine General Pharmaceutical Market No. 1
Yuhan Corp. announced on the 1st that La La Ola, a high content L-arginine product, has achieved the No. 1 sales in the domestic drug arginine market.In accordance with the data on the drug statistics company IQVIA data, 'La La Ola' achieved sales of about 2.9 billion won in 2023 to about 4.5 billion won in 2024, and about 55%of 2024. It grew up, and Yuhan Corp. selected Shin Dong -yeop as an advertising model in May 2024 to strengthen its marketing. Since then, various public relations activities such as TV commercials and campaigns have been enhanced to increase consumer awareness. As a result, the leading position in the arginine market
Read more
2025-03-26 (drugstorenews.com)
Hikma launches cisatracurium besylate, gets OK for Kloxxado in Canada |
Cisatracurium besylate injection has a market value of approximately $14 million in the 12 months ending January 2025, per IQVIA.
Read more
2024-09-18 (expresspharma.in)
Lupin gets US FDA nod for Bumetanide Injection, USP
Bumetanide Injection USP (RLD Bumex) had estimated annual sales of $ 20 million in the US (IQVIA MAT July 2024)
Read more
2024-01-04 (drugstorenews.com)
Lupin receives FDA nod for 3 generics |
The FDA has approved Lupin's generic Alrex, generic Zyloprim and generic Januvia.
Read more